Citations

Clear

3138 citation(s) found for "Smith, AM".

246.3: Regional disparities in hypothermic machine perfusion pump utilization and kidney discard rates in the United States.
Ovdat, Esther , Issa, Naim , Dean, Patrick G. , Tapia, Amanda L. , Smith, Byron H. , Amer, Hatem , Riad, Samy

Mayo Clinic

Transplantation | September 16, 2024 | Volume: 108 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001064752.39861.de Get It

V-213.4: Impact of hypothermic machine perfusion on delayed graft function in kidney pairs from the same deceased donor in the United States.
Mahgoub, Mohammed, Alrifai, Ahmed, Issa, Naim , Dean, Patrick G. , Tapia, Amanda L. , Smith, Byron H. , Amer, Hatem , Riad, Samy

Mayo Clinic

Transplantation | September 16, 2024 | Volume: 108 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001066820.97952.a2 Get It

V-310.5: Predictors of delayed graft function in the United States: A comprehensive multivariable analysis with a focus on hypothermic machine perfusion.
Alrifai, Ahmed, Mahgoub, Mohammed, Naim, Issa S, Dean, Patrick G. , Tapia, Amanda L. , Smith, Byron H. , Amer, Hatem , Riad, Samy

Mayo Clinic

Transplantation | September 16, 2024 | Volume: 108 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001066852.48137.23 Get It

Necessity of posterior osteotomies for mild flexible cervical deformity correction
Eastlack, Robert K. , Lakomkin, Nikita , Tran, Stacie , Jelousi, Michael, Soroceanu, Alex, Passias, Peter, Protopsaltis, Themistocles S. , Klineberg, Eric O. , Hamilton, D. Kojo , Burton, Douglas C. , Shaffrey, Christopher I. , Mundis, Gregory M. , Smith, Justin S. , Bess, Shay R. , Lafage, Virginie , Kim, Han Jo , Ames, Christopher Pearson

Mayo Clinic

Journal of Neurosurgery: Spine | September 14, 2024 | Volume: 41 | Issue: 6 | Pages: 757-764

10.3171/2024.5.spine231223 | PMID 39270323 Get It

OBJECTIVE Correction of mild flexible cervical deformity (CD) via the posterior approach has been described with and without the use of posterior osteotomies (POs), despite a lack of clarity regarding their necessity or risks. The purpose of this study was to determine whether the use of POs when correcting mild flexible CD leads to improved clinical or radiographic outcomes, as well as defining the relative risks in utilizing them. METHODS A prospective multicenter registry of operative CD patients was analyzed. Inclusion criteria were cervical kyphosis > 10°, cervical scoliosis > 10°, cervical sagittal vertical axis (cSVA) > 4 cm, or chin-brow vertical angle > 25°. Mild deformity was defined by a cSVA of 3–5 cm and/or kyphosis < 15°. Flexibility was defined by a C2–7 angular change > 5° on preoperative flexion/extension radiographs. Patients who received a posterior column osteotomy (PCO) (Ames grades 1 and 2) were compared with patients who did not undergo a PCO (noPCO) as well as those who underwent a three-column osteotomy (3CO) (Ames grades 3–6). RESULTS Ninety-five patients (33 PCO, 49 noPCO, 13 3CO) met the inclusion criteria. Both the number of levels fused (9.2 vs 7.7, p = 0.001) and the estimated blood loss (EBL) (1027 vs 486 mL, p = 0.012) were higher in the PCO cohort. Patients in the noPCO group were more likely to have a cervical apex of kyphosis (71.1%, p = 0.046), while those undergoing 3COs were more likely to have a thoracic apex (58.3%, p = 0.005). Preoperative cSVA (PCO vs noPCO: 45.4 vs 37.9 cm, p = 0.084), T1 slope (32.5° vs 29.6°, p = 0.376), C2–7 lordosis (−8.9° vs −9.2°, p = 0.942), and modified Japanese Orthopaedic Association (mJOA) score (13.4 vs 13.5, p = 0.854) were similar; however, both Neck Disability Index (NDI) (55.6 vs 42, p = 0.002) and numeric rating scale (NRS) neck (7.2 vs 5.8, p = 0.028) scores were higher in the PCO group before surgery. When adjusting for the use of an anterior approach, there was no significant difference in 1-year postoperative cSVA (35.7 and 35.6 cm, respectively; p = 0.969), C2–7 lordosis (13.7° and 10.1°, respectively; p = 0.393), and patient-reported outcome measures (NRS, NDI, and mJOA) between the PCO and noPCO groups. Two-year radiographic outcomes were largely similar, except for C2 slope, which was higher in the PCO group (29.1° vs 18°, p = 0.026). The overall complication rates progressively increased with more complex osteotomy use (noPCO 68.8% vs PCO 71.9% vs 3CO 75%) but did not reach significance (p = 0.063). CONCLUSIONS The use of POs for mild flexible adult CD may not be necessary to achieve desirable radiographic correction. They are associated with greater EBL and fusion burden. Further studies are needed to fully delineate the risks of adverse events for various types of osteotomies.
Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer
Greer, Joseph A. , El‐Jawahri, Areej , Rinaldi, Simone , Kamdar, Mihir , Horick, Nora , Pintro, Kedie, Rabideau, Dustin J. , Feliciano, Josephine , Leventakos, Konstantinos , Rabow, Michael W. , Zachariah, Finly , Martin, Sara , Silveira, Maria J. , Shoemaker, Laura, Bauman, Jessica R. , Spoozak, Lori , Grey, Carl, Blackhall, Leslie , Curseen, Kimberly , O’Mahony, Sean , Smith, Melanie , Rhodes, Ramona L. , Cullinan, Amelia , Jackson, Vicki A. , Investigators, REACH PC, Kamdar, Manali , Kamdar, Manali , Temel, Jennifer S. , Park, Elyse R , Schwamm, Lee H. , Chua, Isaac S. , Fischer, Stacy M. , Campbell, Toby C. , Hanson, Laura C. , Bakitas, Marie , Investigators, REACH PC, Horick, Nora

Mayo Clinic

JAMA | September 11, 2024 | Volume: 332 | Issue: 14 | Pages: 1153

10.1001/jama.2024.13964 | PMID 39259563 Get It

Importance Numerous studies show that early palliative care improves quality of life and other key outcomes in patients with advanced cancer and their caregivers, although most lack access to this evidence-based model of care. Objective To evaluate whether delivering early palliative care via secure video vs in-person visits has an equivalent effect on quality of life in patients with advanced non–small cell lung cancer (NSCLC). Design, Setting, and Participants Randomized, multisite, comparative effectiveness trial from June 14, 2018, to May 4, 2023, at 22 US cancer centers among 1250 patients within 12 weeks of diagnosis of advanced NSCLC and 548 caregivers. Intervention Participants were randomized to meet with a specialty-trained palliative care clinician every 4 weeks either via video visit or in person in the outpatient clinic from the time of enrollment and throughout the course of disease. The video visit group had an initial in-person visit to establish rapport, followed by subsequent virtual visits. Main Outcomes and Measures Equivalence of the effect of video visit vs in-person early palliative care on quality of life at week 24 per the Functional Assessment of Cancer Therapy-Lung questionnaire (equivalence margin of ±4 points; score range: 0-136, with higher scores indicating better quality of life). Participants completed study questionnaires at enrollment and at weeks 12, 24, 36, and 48. Results By 24 weeks, participants (mean age, 65.5 years; 54.0% women; 82.7% White) had a mean of 4.7 (video) and 4.9 (in-person) early palliative care encounters. Patient-reported quality-of-life scores were equivalent between groups (video mean, 99.7 vs in-person mean, 97.7; difference, 2.0 [90% CI, 0.1-3.9]; P = .04 for equivalence). Rate of caregiver participation in visits was lower for video vs in-person early palliative care (36.6% vs 49.7%; P &amp;lt; .001). Study groups did not differ in caregiver quality of life, patient coping, or patient and caregiver satisfaction with care, mood symptoms, or prognostic perceptions. Conclusions and Relevance The delivery of early palliative care virtually vs in person demonstrated equivalent effects on quality of life in patients with advanced NSCLC, underscoring the considerable potential for improving access to this evidence-based care model through telehealth delivery. Trial Registration ClinicalTrials.gov Identifier: NCT03375489
Strategic Tasks and Prospects for the Development of the Resource Base of Healthcare and Health Saving through the Prism of Personalized and Precision Medicine
Suchkov, Sergey , Abe, Hiroyuki , Berezhnoy, A. I., Polyakova, V. S. , Vasiliev, Mikhail , Ovchinnikov, A. P., Демидова, В. С. , Земсков, А. М. , Abe, H., Murphy, Susan Allbritton , Smith, D., Zemskov, Vladimir Mikhailovich , Revishvili, Amiran Sh. , Scherman, Daniel , Глинушкин, А. П. , Barach, Paul Randall , Suvorov, A. N.

Mayo Clinic

Успехи современной биологии | September 10, 2024 | Volume: 144 | Issue: 2 | Pages: 137-154

10.31857/s0042132424020021 Get It

Current research indicates the importance of a personalized approach to health care, including quality preclinical laboratory diagnostics, preventive and prophylactic nutrition and the construction of individualized nutritional protocols, and well-being of the microenvironment as a whole. This article analyzes existing methods and technologies in the fields of personalized nutritional, medicine, precision fudomics and bioinformatics and their contribution to healthcare, reviewing key aspects of these fields and suggesting directions for further research and implementation.
Navigating the Postoperative Management of Remifentanil-Induced Hyperalgesia: A Case Report
Smith, Nathan T. , Fernholz, Ryan, Juresic, Sanny

Mayo Clinic

Journal of Pain & Palliative Care Pharmacotherapy | September 9, 2024 | Volume: 38 | Issue: 4 | Pages: 373-378

10.1080/15360288.2024.2400901 | PMID 39250604 Get It

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
Gandhi, Pranav , Lalla, Anjana, Singh, Rashmi B. Halker , McAllister, Peter , Smith, Jonathan H., Dabruzzo, Brett , Chalermpalanupap, Natty, Kelton, Kari , Halker Singh, Rashmi B , Ailani, Jessica , Lalla, Anjana, Nahas, Stephanie J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | September 9, 2024 | Volume: 64 | Issue: 10 | Pages: 1253-1263

10.1111/head.14824 | PMID 39248007 Get It

Abstract Objective To estimate the number needed to treat and cost per additional responder for atogepant and rimegepant versus placebo for the preventive treatment of episodic migraine (EM) in the United States. Background Migraine has an enormous impact on a person's daily activities and quality of life, and results in significant clinical and economic burden to both individuals and society. It is important to understand the comparative efficacy and economic value of oral calcitonin gene–related peptide receptor antagonists (gepants) for preventive treatment of EM. Currently, atogepant and rimegepant are US Food and Drug Administration approved for preventive treatment of migraine (rimegepant for EM and atogepant for EM and for chronic migraine). In the absence of head‐to‐head trials, we utilized an indirect treatment comparison on efficacy data from clinical trials conducted for the preventive treatment of EM. We estimated number needed to treat, a valuable metric used in clinical practice to compare treatment efficacy, and cost per additional responder, which can be used to establish the cost effectiveness of a treatment. Methods An indirect treatment comparison was conducted to compare the efficacy of atogepant 60 mg once daily and rimegepant 75 mg once every other day as preventive treatments for EM using published data from the registrational trials of atogepant (ADVANCE) and rimegepant (BHV3000‐305). The efficacy outcome of interest was ≥50% reduction from baseline in mean monthly migraine/headache days (≥50% responder rate), which was variably defined for a base case and two scenario analyses. Number needed to treat and cost per additional responder versus placebo were calculated and compared between both treatments (weeks 9–12 in the base case analysis; weeks 1–12 and 9–12 for atogepant and during weeks 9–12 for rimegepant in the scenario analyses). Results In the base case analysis, ≥50% responder rates were 64.9% (95% confidence interval [CI], 53.9–74.5) for atogepant and 51.8% (95% CI, 42.9–60.6) for rimegepant, compared to 44.1% (95% CI, 39.4–49.0) for placebo. The median number needed to treat versus placebo in the base case scenario was 4.8 (95% CI, 3.1–9.0) for atogepant compared to 13.0 (95% CI, 5.9–75.1) for rimegepant. The cost per additional responder versus placebo in the base case scenario was estimated to be $15,823 (95% CI, $11,079–$29,516) for atogepant compared to $73,029 (95% CI, $32,901–$422,104) for rimegepant. Results of the two scenario analyses were consistent with the base case analysis. Conclusions Atogepant had substantially lower numbers needed to treat and costs per additional responder versus placebo than rimegepant for the preventive treatment of EM across all evaluated scenarios. These analyses suggest that atogepant may be more cost effective than rimegepant for the preventive treatment of EM. Limitations include differences in inclusion/exclusion criteria and in reporting of the ≥50% responder rates between trials.
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review
Kakkilaya, Apoorva, Trando, Aaron , Cliff, Edward R. Scheffer , Mian, Hira , Aziz, Muhammad , Goodman, Aaron M. , Jeong, Ah‐Reum , Lee‐Smith, Wade , Al Hadidi, Samer , Chakraborty, Rajshekhar , Mohyuddin, Ghulam Rehman , Mian, Hira , Kakkilaya, Apoorva , Kelkar, Amar H , Russler‐Germain, David A. , Mehra, Nikita , Chakraborty, Rajshekhar , Gertz, Morie A. , Mohyuddin, Ghulam Rehman

Mayo Clinic

The Oncologist | September 5, 2024 | Volume: 30 | Issue: 2 | Pages: No page available

10.1093/oncolo/oyae219 | PMID 39236068 Get It

Abstract Background Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on the efficacy or optimal timing of treatment in SMM. We systematically reviewed the landscape of all clinical trials in SMM. We compared the efficacy of treatment regimens studied in SMM to results from these regimens when used in newly diagnosed multiple myeloma (NDMM), to determine whether the data suggest deeper responses in SMM versus NDMM. Methods All prospective interventional clinical trials for SMM, including published studies, meeting abstracts, and unpublished trials listed on ClinicalTrials.gov up to April 1, 2023, were identified. Trial-related variables were captured, including treatment strategy and efficacy results. Relevant clinical endpoints were defined as overall survival (OS) and quality of life. Results Among 45 SMM trials identified, 38 (84.4%) assessed active myeloma drugs, while 7 (15.6%) studied bone-modifying agents alone. Of 18 randomized trials in SMM, only one (5.6%) had a primary endpoint of OS; the most common primary endpoint was progression-free survival (n = 7, 38.9%). Among 32 SMM trials with available results, 9 (28.1%) met their prespecified primary endpoint, of which 5 were single-arm studies. Six treatment regimens were tested in both SMM and NDMM; 5 regimens yielded a lower rate of very good partial response rate or better (≥VGPR) in SMM compared to the corresponding NDMM trial (32% vs 63%, 43% vs 53%, 40% vs 63%, 86% vs 89%, 92% vs 95%, and 94% vs 87%, respectively). Conclusion In this systematic review of all prospective interventional clinical trials in SMM, we found significant variability in trial design, including randomization status, primary endpoints, and types of intervention used. Despite the statistical limitations, comparison of treatment regimens revealed no compelling evidence that the treatment is more effective when introduced early in SMM compared to NDMM.
Bridging clinical informatics and implementation science to improve cancer symptom management in ambulatory oncology practices: experiences from the IMPACT consortium
McCleary, Nadine J. , Merle, James L. , Richardson, Joshua E. , Garcia, Sofia F. , Tesch, Nathan , DiMartino, Lisa , Hassett, Michael J. , Cella, David , Smith, Justin D. , Kroner, Barbara L, Ruddy, Kathryn, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Cahue, September, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Faris, Nicolas, Flores, Anne Marie, Garcia, Martha, Hodgdon, Christine, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearson, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Richardson, Kimberly, Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tramontano, Angela C. , Wong, Sandra , Cella, David , Garcia, Sofia F , Bass, Michael , Cheville, Andrea , Mitchell, Sandra A , Jensen, Roxanne E. , Minteer, Sarah A. , Austin, Jessica D. , Osarogiagbon, Raymond U. , Wong, Sandra L. , Schrag, Deborah , Smith, Ashley Wilder , Kroner, Barbara L, Griffin, Joan M. , Ruddy, Kathryn J. , Ardini, Mary-Anne , Barrett, Fiona, Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Popovic, Jennifer R. , Preiss, Liliana , Reich, James, Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JAMIA Open | September 5, 2024 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/jamiaopen/ooae081 | PMID 39234146 Get It

AbstractObjectivesTo report lessons from integrating the methods and perspectives of clinical informatics (CI) and implementation science (IS) in the context of Improving the Management of symPtoms during and following Cancer Treatment (IMPACT) Consortium pragmatic trials.Materials and MethodsIMPACT informaticists, trialists, and implementation scientists met to identify challenges and solutions by examining robust case examples from 3 Research Centers that are deploying systematic symptom assessment and management interventions via electronic health records (EHRs). Investigators discussed data collection and CI challenges, implementation strategies, and lessons learned.ResultsCI implementation strategies and EHRs systems were utilized to collect and act upon symptoms and impairments in functioning via electronic patient-reported outcomes (ePRO) captured in ambulatory oncology settings. Limited EHR functionality and data collection capabilities constrained the ability to address IS questions. Collecting ePRO data required significant planning and organizational champions adept at navigating ambiguity.DiscussionBringing together CI and IS perspectives offers critical opportunities for monitoring and managing cancer symptoms via ePROs. Discussions between CI and IS researchers identified and addressed gaps between applied informatics implementation and theory-based IS trial and evaluation methods. The use of common terminology may foster shared mental models between CI and IS communities to enhance EHR design to more effectively facilitate ePRO implementation and clinical responses.ConclusionImplementation of ePROs in ambulatory oncology clinics benefits from common understanding of the concepts, lexicon, and incentives between CI implementers and IS researchers to facilitate and measure the results of implementation efforts.